Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA Poster 临床前数据暴露无法预测双特异性 T 细胞吸引剂在实体瘤适应症中的临床生理活性剂量;是否有更好的衡量标准?— 来自小型机制性 MBMA 的启示 Danielle Pillsbury2024 年 12 月 11 日
Optimizing Clinical Development: Saving Time and Costs Case Study 优化临床开发:节约时间和成本 战略机械建模解决方案可帮助免疫肿瘤生物技术加速其新型疗法的临床开发。Danielle Pillsbury2024 年 8 月 16 日
Systems Modeling Delivers Efficiencies and Savings in Clinical Development Case Study 系统建模在临床开发中显著提升效率并降低成本 Discover how an IO-focused company developing immunotherapies applied QSP modeling solutions for cost-effective clinical development.…Danielle Pillsbury2024 年 7 月 12 日
Quantitative Systems Pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm Publication Quantitative Systems Pharmacology approaches for immuno‐oncology: adding virtual patients to the development paradigm Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit…Jieun Choe2020 年 7 月 26 日